Content
The content of medical knowledge in this section of the site of the Lactology Foundation is intended for the practical needs of doctors, pharmacists and students in these specialties. It is more than reasonable to consult other authoritative medical sources before using our medical knowledge.
- Lung in Health and Disease
- General Approach to Patients
With Respiratory Disorders - Evaluating Lung Structure and Function
- Interstitial Lung Diseases
- Pulmonary Vascular Diseases
- Disorders of the Pleura,
Mediastinum, and Chest Wall - Respiratory Failure
- Lung Transplantation
- Perioperative Pulmonary Management
- COVID-19 Pulmonary Management
- Congenital Lung Malformations
- Sleep-Related Disorders
General Approach to Patients With Respiratory Disorders
As with the evaluation of most
patients, the approach to a patient
with a respiratory system disorder
begins with a thorough history and a
focused physical examination. Many
patients will subsequently undergo
pulmonary function testing, chest
imaging, blood and sputum analysis,
a variety of serologic or
microbiologic studies, and
diagnostic procedures, such as
bronchoscopy.
This stepwise
approach is discussed in detail
below.
HISTORY
Dyspnea and Cough
The cardinal
symptoms of respiratory disease are dyspnea and
cough. Dyspnea has many causes, some of which
are not predominantly due to lung pathology. The
words a patient uses to describe shortness of
breath can suggest certain etiologies for
dyspnea. Patients with obstructive lung disease
often complain of “chest tightness” or
“inability to get a deep breath,” whereas
patients with congestive heart failure more
commonly report “air hunger” or a sense of
suffocation. The tempo of onset and the duration
of a patient’s dyspnea are likewise helpful in
determining the etiology. Acute shortness of
breath is usually associated with sudden
physiological changes, such as laryngeal edema,
bronchospasm, myocardial infarction, pulmonary
embolism, or pneumothorax. Patients with COPD
and idiopathic pulmonary fibrosis (IPF)
experience a gradual progression of dyspnea on
exertion, punctuated by acute exacerbations of
shortness of breath. In contrast, most
asthmatics do not have daily symptoms, but
experience intermittent episodes of dyspnea,
cough, and chest tightness that are usually
associated with specific triggers, such as an
upper respiratory tract infection or exposure to
allergens.
Specific questioning should focus
on factors that incite dyspnea as well as on any
intervention that helps resolve the patient’s
shortness of breath. Asthma is commonly
exacerbated by specific triggers, although this
can also be true of COPD. Many patients with
lung disease report dyspnea on exertion.
Determining the degree of activity that results
in shortness of breath gives the clinician a
gauge of the patient’s degree of disability.
Many patients adapt their level of activity to
accommodate progressive limitation. For this
reason, it is important, particularly in older
patients, to delineate the activities in which
they engage and how these activities have
changed over time. Dyspnea on exertion is often
an early symptom of underlying lung or heart
disease and warrants a thorough evaluation.For
cough, the clinician should inquire about the
duration of the cough, whether or not it is
associated with sputum production, and any
specific triggers that induce it. Acute cough
productive of phlegm is often a symptom of
infection of the respiratory system, including
processes affecting the upper airway (e.g.,
sinusitis, tracheitis), the lower airways (e.g.,
bronchitis, bronchiectasis), and the lung
parenchyma (e.g., pneumonia). Both the quantity
and quality of the sputum, including whether it
is blood-streaked or frankly bloody, should be
determined.
Hemoptysis warrants urgent
evaluation.
Chronic cough (defined as that
persisting for >8 weeks) is commonly associated
with obstructive lung diseases, particularly
asthma, COPD and chronic bronchiectasis, as well
as “nonrespiratory” diseases, such as
gastroesophageal reflux and postnasal drip.
Diffuse parenchymal lung diseases, including
IPF, frequently present as a persistent,
nonproductive cough. All causes of cough are not
respiratory in origin, and assessment should
encompass a broad differential, including
cardiac and gastrointestinal diseases as well as
psychogenic causes.
Additional Symptoms
Patients with
respiratory disease may report wheezing, which
is suggestive of airways disease, particularly
asthma. Hemoptysis can be a symptom of a variety
of lung diseases, including infections of the
respiratory tract, bronchogenic carcinoma, and
pulmonary embolism. In addition, chest pain or
discomfort can be respiratory in origin. As the
lung parenchyma is not innervated with pain
fibers, pain in the chest from respiratory
disorders usually results from either diseases
of the parietal pleura (e.g., pneumothorax) or
pulmonary vascular diseases (e.g., pulmonary
hypertension). As many diseases of the lung can
result in strain on the right side of the heart,
patients may also present with symptoms of cor
pulmonale, including abdominal bloating or
distention and pedal edema.
Additional History
A thorough social
history is an essential component of the
evaluation of patients with respiratory disease.
All patients should be asked about current or
previous cigarette smoking, as this exposure is
associated with many diseases of the respiratory
system, including COPD, bronchogenic lung
cancer, and select parenchymal lung diseases
(e.g., desquamative interstitial pneumonitis and
pulmonary Langerhans cell histiocytosis). For
most of these disorders, increased cigarette
smoke exposure (i.e., cigarette pack-years)
increases the risk of disease. “Secondhand
smoke” also increases risk for some respiratory
disorders, so patients should also be asked
about parents, spouses, or housemates who smoke.
Possible inhalational exposures at work (e.g.,
asbestos, silica) or home (e.g., wood smoke,
excrement from pet birds) should be explored.
Travel predisposes to certain infections of the
respiratory tract, most notably tuberculosis.
Potential exposure to fungi is increased in
specific geographic regions or climates (e.g.,
Histoplasma capsulatum), so exposures to these
regions should be determined. Associated
symptoms of fever and chills should raise the
suspicion of infective etiologies, both
pulmonary and systemic. A comprehensive review
of systems may suggest rheumatologic or
autoimmune disease presenting with respiratory
tract manifestations. Questions should focus on
joint pain or swelling, rashes, dry eyes, dry
mouth, or constitutional symptoms. In addition,
carcinomas from a variety of primary sources
commonly metastasize to the lung and cause
respiratory symptoms. Finally, therapy for other
conditions, including both irradiation and
medications, can result in diseases of the
chest.
Please see also our Toxilact data base which is in the following language versions:
Toxilact Deutsche Sprachversion
Toxilact Nederlandstalige versie
Toxilakt έκδοση στην ελληνική γλώσσα
Toxilact English language version
Toxilact magyar nyelvű változat
Toxilact versione in lingua italiana
Toxilact polska wersja językowa
Pulmonary symptoms, findings and investigations
Cough
Expectoration
Hemoptysis
Pleural Effusion
Approach to wheezing in children
Polysomnography
Pulmonary Function Testing
Toxicological risk during lactation
Toxicological lactation category I - the drug and/or its metabolites are either not eliminated through breast milk or are not toxic to the newborn and cannot lead to the development of absolutely any toxic reactions and adverse consequences for his health in the near and long term. Breast-feeding does not need to be discontinued while taking a given drug that falls into this toxicological lactation category.
Toxicological lactation category II - the drug and its metabolites are also eliminated through breast milk, but the plasma:milk ratio is very low and/or the excreted amounts cannot generate toxic reactions in the newborn due to various reasons, including degradation of the drug in the acid pool of the stomach of the newborn. Breastfeeding does not need to be discontinued while taking this medicine.
Toxicological lactation category III - the drug and/or its metabolites generate in breast milk equal to plasma concentrations or higher, and therefore the possible development of toxic reactions in the newborn can be expected. Breastfeeding should be discontinued for the period corresponding to the complete elimination of the drug or its metabolites from the mother's plasma.
Toxicological lactation category IV - the drug and/or its metabolites generate a plasma:milk ratio of 1:1 or higher and/or have a highly toxic profile for both the mother and the newborn, therefore their administration is incompatible with breastfeeding and it should to stop completely, and not just for the period of taking the drug, or to look for a less toxic therapeutic alternative.